{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2001"],"condition":["Colorectal Cancer","Colorectal Neoplasms"],"disease":["Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2006602"],"location":["United States"],"study_start_month":["5"],"keyword":["Recurrent rectal cancer","Recurrent colon cancer","Stage IV rectal cancer","Irinotecan","Stage III rectal cancer","Capecitabine","Stage IV colon cancer","Adenocarcinoma of the colon","Adenocarcinoma of the rectum","Stage III colon cancer"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer","description":"PURPOSE: Phase II trial to study the effectiveness of combining capecitabine and irinotecan in treating patients who have locally advanced, recurrent, or metastatic colorectal cancer.","dates":{"creation":"2001-05-15"},"accession":"2006602","cross_references":{"ClinicalTrials___gov":["NCT00022698"]}}